The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer ...

“Onco360 is grateful for the opportunity to partner with the team at Nuvation Bio and become a specialty pharmacy provider for IBTROZI,” said Benito Fernandez, Chief Commercial Officer at Onco360. “We ...

Strong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use. Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor ...

Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc. Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% ...

If coadministration with a moderate CYP3A inhibitor cannot be avoided in patients with Advanced SM, reduce dose of AYVAKIT. Avoid coadministration of AYVAKIT with strong or moderate CYP3A inducers.

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA ® (zanubrutinib) ...

Strong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use. Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor ...

CYP3A Inhibitors: When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA ...

When Vanrafia is taken with these CYP3A inducers, it may not work as well to treat your IgAN. Ideally, Vanrafia should not be taken together with OATP1B1/1B3 inhibitors or strong or moderate CYP3A ...

maraviroc Selzentry 150mg, 300mg tabs Adults: Concomitant potent CYP3A inhibitors (with or without a potent CYP3A inducer): 150mg twice daily. Noninteracting concomitant drugs, including ...